Minnesota Senate Bill SF3087

Minnesota 2025-2026 Regular Session

• Introduced: 3/27/25
• Refer: 3/27/25

Caption

Restrictions placed on the sale of certain over-the-counter allergy medications modifications

Summary

SF3087 amends Minnesota’s controlled substances law governing methamphetamine precursor drugs, which are over-the-counter products containing ephedrine or pseudoephedrine. The bill tightens and reorganizes the rules for retail sales of these products, including limits on the number of packages and total grams that may be sold in a single transaction and within a 30-day period. It also requires sales to be made from behind a checkout counter by a pharmacist, pharmacy technician, or pharmacy clerk, and requires buyers to show photo identification and sign a sales log that must be retained for three years. The bill also continues and clarifies several exemptions and enforcement provisions. It exempts certain pediatric products, gel capsules, liquids, certified tamper-resistant products, and some low-percentage powder products. It preserves misdemeanor penalties for knowing violations, provides a defense for sellers who reasonably rely on acceptable proof of age, and shields business owners from liability if they lacked knowledge of an employee’s violation and had a training program in place. Finally, it expressly preempts local ordinances regulating over-the-counter sales of ephedrine or pseudoephedrine, voiding prior local rules.

Impact

The bill would amend Minnesota Statutes section 152.02, subdivision 6, by revising the state’s Schedule V restrictions on methamphetamine precursor drugs and related retail-sale controls. It affects pharmacies, retail stores, employees who sell these products, buyers under age 18, and law enforcement through recordkeeping and inspection provisions. It also centralizes regulation at the state level by preempting local ordinances governing over-the-counter ephedrine and pseudoephedrine sales.

Sentiment

No committee transcript or vote record is available, so sentiment must be inferred from the bill text and authorship. The bill appears to reflect a public-safety and anti-diversion approach aimed at limiting access to precursor chemicals used in methamphetamine production while preserving access to common allergy and cold medicines. The inclusion of exemptions for certain product forms and certified products suggests an effort to balance enforcement with legitimate consumer access.

Contention

The main point of contention is likely the tradeoff between restricting diversion of pseudoephedrine and preserving convenient over-the-counter access for consumers who use these medicines for legitimate medical purposes. Retailers and pharmacy operators may also be concerned about the added compliance burden, identification checks, sales logs, storage/display rules, and potential criminal liability for employees. Another likely issue is the bill’s express preemption of local ordinances, which removes local flexibility and could be controversial for jurisdictions that have adopted stricter rules.